Are available at your patients' convenience through in-home visits and through our Kineret support line. Our nurses are here to provide your patients with
One-on-one injection training
Answers to Kineret-related questions
Helpful tips on treatment management
An expert for your patients to call when they are in need
Reports will be given to you and your staff on any discussions had with your patients.
Kineret Case Managers
Are just a call away to help guide you and your patients through the insurance approval process and/or help with financial needs. Our case managers can assist with
Insurance coverage verification
Financial assistance for eligible patients
Kineret Pharmacy Specialists
Can help your patients get their prescription as well as the information they need to get the most out of the KINERET On TRACK program. Our pharmacy specialists, including Kineret clinical pharmacists and certified pharmacy technicians, are here to help your patients with
Enrollment into the KINERET On TRACK program
At-home or in-office prescription delivery
Refill reminders and deliveries to their home or to your office
Educational materials to help set expectations
Kineret is only available through the KINERET On TRACK program.
To get started, download our enrollment forms here.
If you have questions, please call 866-547-0644 from 8:00 a.m to 8:00 p.m ET, Monday through Friday, to speak with a specialist.
Kineret® is an interleukin-1 receptor antagonist indicated for:
Rheumatoid Arthritis (RA)
Reduction in signs and symptoms and slowing the progression of structural damage in moderately to severely active rheumatoid arthritis, in patients 18 years of age or older who have failed 1 or more disease-modifying antirheumatic drugs (DMARDs).
Cryopyrin-Associated Periodic Syndromes (CAPS)
Treatment of Neonatal-Onset Multisystem Inflammatory Disease (NOMID)
IMPORTANT SAFETY INFORMATION
Kineret is contraindicated in patients with known hypersensitivity to E. coli-derived proteins, Kineret, or to any components of the product
In RA, discontinue use if serious infection develops. In Kineret-treated NOMID patients, the risk of a NOMID flare when discontinuing Kineret treatment should be weighed against the potential risk of continued treatment. Do not initiate Kineret in patients with active infections
Use in combination with Tumor Necrosis Factor (TNF) blocking agents is not recommended
Hypersensitivity reactions, including anaphylactic reactions and angioedema, have been reported
The impact of treatment with Kineret on active and/or chronic infections and the development of malignancies is not known
Live vaccines should not be given concurrently with Kineret
Neutrophil counts should be assessed prior to initiating Kineret treatment, and while receiving Kineret, monthly for 3 months, and thereafter quarterly for a period up to 1 year
RA: Most common adverse reactions (incidence ≥ 5%) are injection site reaction, worsening of rheumatoid arthritis, upper respiratory tract infection, headache, nausea, diarrhea, sinusitis, arthralgia, flu-like symptoms, and abdominal pain
NOMID: The most common AEs during the first 6 months of treatment (incidence > 10%) are injection site reaction, headache, vomiting, arthralgia, pyrexia, and nasopharyngitis
A higher rate of serious infections has been observed in RA patients treated with concurrent Kineret and etanercept therapy than in patients treated with etanercept alone. Use of Kineret in combination with TNF blocking agents is not recommended
Because there is a higher rate of infections in the elderly population in general, caution should be used in treating the elderly
Kineret is substantially excreted by the kidney, and the risk of toxic reactions to Kineret may be greater in patients with impaired renal function